Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Identification of the anti-COVID-19 mechanism of action of Han-Shi Blocking Lung using network pharmacology-integrated molecular docking

Chong Yuan¹, Fei Wang¹, Peng-Yu Chen¹, Zong-Chao Hong¹, Yan-Fang Yang^1,2, He-Zhen Wu^1,2

¹Faculty of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065; ²Key Laboratory of Traditional Chinese Medicine Resources and Chemistry of Hubei Province, Wuhan 430061, China.

For correspondence:- He-Zhen Wu Email: yyf0204@hbtcm.edu.cn Tel:+8613545341663

Accepted: 16 May 2021 Published: 30 June 2021

Citation: Yuan C, Wang F, Chen P, Hong Z, Yang Y, Wu H. Identification of the anti-COVID-19 mechanism of action of Han-Shi Blocking Lung using network pharmacology-integrated molecular docking. Trop J Pharm Res 2021; 20(6):1241-1249 doi: 10.4314/tjpr.v20i6.21

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the bio-active components and the potential mechanism of the prescription remedy, Han-Shi blocking lung, with network pharmacology with a view to expanding its application.

Methods: Chemical components were first collected from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Pharmmapper database and GeneCards were used to predict the targets related to active components and COVID-19. Using DAVIDE and KOBAS 3.0 databases, Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were enriched. A “components-targets-pathways” (C-T-P) network was conducted by Cytoscape 3.7.1 software. With the aid of Discovery Studio 2016 software, bio-active components were selected to dock with SARS-COV-2 3CL and ACE2.

Results: From the prescription, 47 bio-active components, 83 targets and 103 signaling pathways were obtained in total (p < 0.05). 126 GO entries (p < 0.05) were screened by GO enrichment analysis. Molecular docking results showed that procyanidin B1 eriodictyol, (4E, 6E)-1, 7-bis(4-hydroxyphenyl)hepta-4, 6-dien-3-one, and quercetin had higher docking scores with SARS-COV-2 3CL and ACE2.

Conclusion: With network pharmacology and molecular docking, the bio-active components and targets of this prescription, Han-Shi blocking lung, against COVID-19 were identified. Taken together, this study provided a basis for the treatment of COVID-19 and further promotion of this prescription.

Keywords: Prescription, Han-Shi blocking lung, COVID-19, Mechanism of action, Bioactive components, Network pharmacology, Molecular docking